Native-RISE (Risk Identification for Suicide and Enhanced Care)
Launched by JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH · Jan 15, 2025
Trial Information
Current as of September 28, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Native-RISE is a research study testing a new approach to preventing suicide in Native American communities. It uses a computer risk tool that looks at health data from visits to predict who might be at higher risk within the next 90 days, and then provides brief, supportive follow-up contact from case managers. The study is being done in three Indian Health Service clinics (Chinle, Whiteriver, and Shiprock) that serve the White Mountain Apache and Navajo Nation communities. It’s a randomized, single-blind trial, meaning the care teams won’t know which group a participant is assigned to, to help show whether the combination of risk identification and follow-up support works in real-world clinics.
Eligibility includes adults aged 18 to 75 who have had at least one visit to one of the participating clinics and are identified as at elevated risk either by the existing methods or by the Native-RISE model. There are no listed exclusion criteria. About 1,687 people are planned to enroll. Participants are randomly assigned to one of four groups that vary by whether the algorithm is used and whether providers are notified of risk, with care providers masked to assignment. Those in the intervention groups may receive a risk notification and a resource card, plus brief case-manager contacts over the first year. The main outcome is the rate of suicide attempts within 12 months; a secondary outcome is the number of case-manager contacts (three or more within the first year). Enrollment started in 2024 and is expected to continue through 2028.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18-75
- • Visit at least one of the three participating IHS clinics
- • Identified as at risk of suicide by either an existing method or the new Native-RISE risk model algorithm
- Exclusion Criteria:
- • None
About Johns Hopkins Bloomberg School Of Public Health
The Johns Hopkins Bloomberg School of Public Health is a leading institution dedicated to advancing public health research and education. Renowned for its rigorous academic programs and commitment to improving global health outcomes, the School conducts innovative clinical trials that address pressing health challenges. With a focus on evidence-based practices, multidisciplinary collaboration, and community engagement, the Bloomberg School leverages its extensive resources and expertise to contribute to the development of effective public health interventions and policies. Through its research endeavors, the School aims to enhance population health and inform health policy both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Whiteriver, Arizona, United States
Shiprock, New Mexico, United States
Chinle, Arizona, United States
Patients applied
Trial Officials
Emily Haroz, PhD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported